Prostaglandin FP receptor agonists in the treatment of glaucoma and ocular hypertension: a literature review.

Sophia Moshegov, Nathan Mitchell Kerr

Expert opinion on investigational drugs 2023 Jul-Dec

filter terms:

Glaucoma is a leading cause of blindness with intraocular pressure (IOP) as the only known modifiable risk factor. Prostaglandin FP receptor agonists are the first-line medical treatment for glaucoma and ocular hypertension. Despite their efficacy, their IOP lowering effect may be insufficient requiring second agents, and poor patient compliance to medical therapy may preclude their full effect. This literature review examines the novel FP receptor drugs and drug delivery devices in clinical phase trials for treatment of glaucoma. Three novel drugs targeting FP receptors were identified, including latanoprostene bunod, NCX 470, and sepetaprost. Additionally, sustained drug delivery devices in early clinical phase trials included intracameral implants, punctal plugs, ocular rings, and contact lenses. NO hybrid FP receptor agonists and dual FP/EP3 receptor agonists may show promise as novel medical therapies with greater efficacy than approved prostaglandin analogs in clinical use, with a similar safety profile. Alternatively, drug delivery systems may provide a similar IOP lowering effect to existing agonists but overcome issues with patient compliance and convenience. A personalized approach to drug delivery devices may be required to ensure the most appropriate fit for the patient according to the invasiveness and duration of therapy desired.

Citation

Sophia Moshegov, Nathan Mitchell Kerr. Prostaglandin FP receptor agonists in the treatment of glaucoma and ocular hypertension: a literature review. Expert opinion on investigational drugs. 2023 Jul-Dec;32(11):1017-1023